Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,362 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma.
Kotecha RR, Gedvilaite E, Ptashkin R, Knezevic A, Murray S, Johnson I, Shapnik N, Feldman DR, Carlo MI, Shah NJ, Dunigan M, Huberman K, Benayed R, Zehir A, Berger MF, Ladanyi M, Tsui DWY, Motzer RJ, Lee CH, Voss MH. Kotecha RR, et al. Among authors: murray s. JCO Precis Oncol. 2022 Jul;6:e2200012. doi: 10.1200/PO.22.00012. JCO Precis Oncol. 2022. PMID: 35797508 Free PMC article.
Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy.
Carlo MI, Attalla K, Mazaheri Y, Gupta S, Yildirim O, Murray SJ, Coskey DT, Kotecha R, Lee CH, Feldman DR, Russo P, Patil S, Motzer RJ, Coleman JA, Durack JC, Chen YB, Akin O, Ari Hakimi A, Voss MH. Carlo MI, et al. Among authors: murray sj. Eur Urol. 2022 Jun;81(6):570-573. doi: 10.1016/j.eururo.2022.01.043. Epub 2022 Feb 17. Eur Urol. 2022. PMID: 35183395 Free PMC article. Clinical Trial.
Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial.
Feldman DR, Ged Y, Lee CH, Knezevic A, Molina AM, Chen YB, Chaim J, Coskey DT, Murray S, Tickoo SK, Reuter VE, Patil S, Xiao H, Aghalar J, Apollo AJ, Carlo MI, Motzer RJ, Voss MH. Feldman DR, et al. Among authors: murray s. Cancer. 2020 Dec 15;126(24):5247-5255. doi: 10.1002/cncr.33148. Epub 2020 Sep 25. Cancer. 2020. PMID: 32975815 Free PMC article. Clinical Trial.
Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma.
Gleeson JP, Nikolovski I, Dinatale R, Zucker M, Knezevic A, Patil S, Ged Y, Kotecha RR, Shapnik N, Murray S, Russo P, Coleman J, Lee CH, Stadler ZK, Hakimi AA, Feldman DR, Motzer RJ, Reznik E, Voss MH, Chen YB, Carlo MI. Gleeson JP, et al. Among authors: murray s. Clin Cancer Res. 2021 May 15;27(10):2910-2919. doi: 10.1158/1078-0432.CCR-20-4367. Epub 2021 Mar 3. Clin Cancer Res. 2021. PMID: 33658299 Free PMC article.
High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab.
Lee CH, DiNatale RG, Chowell D, Krishna C, Makarov V, Valero C, Vuong L, Lee M, Weiss K, Hoen D, Morris L, Reznik E, Murray S, Kotecha R, Voss MH, Carlo MI, Feldman D, Sachdev P, Adachi Y, Minoshima Y, Matsui J, Funahashi Y, Nomoto K, Hakimi AA, Motzer RJ, Chan TA. Lee CH, et al. Among authors: murray s. Mol Cancer Res. 2021 Sep;19(9):1510-1521. doi: 10.1158/1541-7786.MCR-21-0053. Epub 2021 May 26. Mol Cancer Res. 2021. PMID: 34039647 Free PMC article. Clinical Trial.
3,362 results